Evidence map›Paper›PMID 42444104›Full record

ReviewThe American journal of case reports2026

Primary Small Cell Neuroendocrine Carcinoma of the Breast in a 75-Year-Old Woman With Aggressive Recurrence Despite Multimodal Therapy: A Case Report and Literature Review.

Shefa Abdullah Alamoudi, Hadeel Elwaheidi, Hanan Albishi, Sarah Aldosari, Asma M Tulbah, Wafa Alkhayal

Abstract readCase ReportsReview
In one paragraph

Review in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shefa Abdullah AlamoudiCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.ORCID 0009-0009-4779-1579
Hadeel ElwaheidiCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Hanan AlbishiDepartment of General Surgery, King Abdullah Hospital, Bisha, Saudi Arabia.
Sarah AldosariDepartment of Surgery, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-5351-4078
Asma M TulbahDivision of Pathology and Laboratory Medicine, Department of Anatomic Pathology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Wafa AlkhayalDepartment of Breast and Endocrine Surgery, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Neuroendocrine breast tumors represent an uncommon subtype of breast cancer, accounting for less than 1% of all breast malignancies and fewer than 0.1% of all neuroendocrine tumors. Their histological and immunophenotypic features closely resemble neuroendocrine neoplasms of other organs, and diagnosis requires careful exclusion of extramammary primaries. CASE REPORT We present the case of a 75-year-old woman diagnosed with primary small cell neuroendocrine breast carcinoma following an incidental detection of a right breast mass. She underwent a simple mastectomy with sentinel lymph node biopsy, followed by adjuvant carboplatin-etoposide chemotherapy. One year later, she developed a solitary hepatic metastasis, which was successfully treated with metastasectomy and repeat adjuvant chemotherapy. Despite initial responses, subsequent surveillance imaging demonstrated progressive hepatic metastatic disease. This case underscores the aggressive clinical behavior and diagnostic challenges associated with high-grade neuroendocrine breast tumors. The 2019 WHO classification highlights the importance of distinguishing neuroendocrine carcinoma subtypes due to differing prognostic and therapeutic implications. Although multiple treatment modalities exist, outcomes remain poor in high-grade or advanced disease. CONCLUSIONS Neuroendocrine breast tumors remain insufficiently understood because of their rarity. This report highlights the importance of thorough histopathological evaluation, meticulous exclusion of extramammary primaries, and close longitudinal follow-up. Additional research is needed to establish standardized diagnostic and therapeutic guidelines.

Indexed as

Breast NeoplasmsCarcinoma, NeuroendocrineCarcinoma, Small CellLiver NeoplasmsNeoplasm Recurrence, LocalAgedCombined Modality TherapyFemaleHumans

Identifiers

PMID42444104
PMCPMC13380115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.